image: Pal-DMPOP由CD47/SIRPα的阻断肽、PD-1/PD-L1的D肽阻断剂，以及N端的棕榈酸尾巴和linker组成，该设计能让Pal-DMPOP抵抗血清中酶的 ...

二、乳腺癌免疫检查点的神秘面纱 目前，在乳腺癌细胞上已发现多种主要的免疫检查点，包括 CD47、CD24、PD-L1、MHC-I 和 STC-1 等。然而，这些免疫检查点在乳腺癌发生、转移以及免疫逃逸过程中所扮演的具体角色，至今尚未完全明晰。它们如同隐藏在黑暗中的谜题 ...

ImmuneOnco Biopharmaceuticals has shown Chinese biotechs are far from immune to the pressures to prioritize pipelines. | ...

CD47-amyloid-β-CD74 signaling is a key driver of adaptive immunosuppression in sepsis, suppressing B cells and impairing ...

PD-(L)1抑制剂改变了肿瘤治疗格局，既是第一代肿瘤免疫的基石，也是目前双/多抗、联合疗法，以及ADC开发的重点方向。 另 ...

On the commercial front, Akeso's adjustments in drug pricing and optimization of its commercial systems led to new drug sales revenue surpassing RMB 2 billion in 2024, a 25% year-on-year increase. The ...

Roche and biotech Forty Seven are developing a similar CD47/PD-L1 combination and South Korean biotech ImmuneOncia is also exploring combinations of anti-CD47 and PD-1 and PD-L1 drugs. And by ...

durvalumab + chemotherapy as 1L treatment for biliary tract cancer Ivonescimab + AK117 (CD47 mAb) vs. pembrolizumab as 1L treatment for PD-L1+ head and neck squamous cell carcinoma (HNSCC ...

Currently, ivonescimab is in 12 registrational/Phase III clinical trials, including 6 head-to-head studies against PD-1/L1 therapies, as well as in over 20 Phase II trials. Ivonescimab + chemotherapy ...

ivonescimab outperforms pembrolizumab in Phase III study for first-line PD-L1+ NSCLC: mPFS HR=0.51 ... Reimbursement Drug List (NRDL). AK117 (CD47) enters Phase III trials: ivonescimab combined ...